Form Type:  8-K
Filing Date:  6/8/2020 
CIK:  0001434418 
Address:  215 FIRST STREET
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-714-0555 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.79 (3.44%)  
Trade Time: 
Oct 22  
Market Cap: 
Trade CNST now with 

© 2020  
Description of Business
We are a clinical-stage biopharmaceutical company using our expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Our integrated epigenetics platform enables us to validate targets and generate small molecules impacting these targets to selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. This platform reflects our deep understanding of the biology of regulation of gene expression by epigenetic regulatory proteins, or epigenetic regulators, the development of small-molecule product candidates that selectively modulate their activity, and the design of clinical development programs supported by novel biomarker strategies. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.
Register and access this filing in:     
  FORM 8-K
      Item 5.02 Departure of Directors or Certain Officers; ...